Wegovy on the NHS: the NICE guidance explained

What NICE TA875 actually says about Wegovy eligibility

NICE's technology appraisal TA875, published in March 2023, found semaglutide 2.4mg cost-effective for the NHS under defined conditions. Adults must have a BMI of 35 or above and at least one weight-related comorbidity, high blood pressure, type 2 diabetes, dyslipidaemia, sleep apnoea or cardiovascular disease are the most commonly cited. For people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, the BMI threshold drops by 2.5 kg/m², so a qualifying BMI of 32.5 or above may be sufficient.

Two further conditions shape access in practice. First, treatment must be delivered as part of a specialist weight management service that provides multidisciplinary support, dietary advice, physical activity guidance, and behavioural input alongside the medicine. Second, NICE sets a hard ceiling of two years on NHS semaglutide use. Clinicians are also guided to reconsider continuing the medicine if a patient has lost less than five percent of their body weight after six months on the maintenance dose. The STEP 1 trial, published in the New England Journal of Medicine, showed an average reduction of around 15% in body weight over 68 weeks at the 2.4mg dose, the evidence base NICE assessed. Real-world results vary.

A common misconception is that a GP can simply write a Wegovy prescription once a patient meets the BMI number. In practice, NHS access flows through specialist services, where the BMI threshold is necessary but not sufficient on its own, and those services carry their own waiting lists.

Wegovy on the NHS versus private treatment: the practical gap

For people who meet the NICE criteria, NHS Wegovy is the most affordable route in theory. In practice, specialist weight management services operate with significant waiting times in most areas. NHS England's guidance on weight-management injections confirms that eligibility and active enrolment in wraparound care are both required before treatment begins.

Private treatment works differently. There is no referral pathway and no waiting list. A clinician-led online pharmacy can assess suitability through a structured consultation (checking BMI, relevant conditions, contraindications and medical history) and, where appropriate, issue a prescription. The two-year NICE ceiling is an NHS commissioning rule, not a licensed limit; a private prescriber makes ongoing clinical judgements without that administrative cut-off. That said, private treatment comes at a cost that the NHS route avoids, and it is worth understanding exactly what a legitimate service charges before deciding.

Private access is also worth considering for people whose BMI sits below 35 but above 27, with a relevant comorbidity, the licensed threshold for semaglutide is lower than the NICE NHS threshold, so some people who do not qualify for NHS treatment may qualify privately.

How the MHRA approval and the 7.2mg dose change the picture

NICE TA875 assessed the 2.4mg weekly maintenance dose because that was the only licensed strength when the appraisal was conducted. The landscape has since moved. The MHRA approved a higher 7.2mg maintenance dose, and on 14 April 2026 approved a dedicated single-dose 7.2mg pen, one pre-set weekly injection, with an auto-dosing mechanism and a covered needle that locks after use. Trial data at 7.2mg showed average weight loss of around 20.7% over 72 weeks, narrowing the gap with tirzepatide results considerably.

Whether the NHS will commission the 7.2mg dose is a separate question; NICE appraisals do not automatically update when a new dose receives MHRA approval. For now, the 7.2mg pen is available through private prescription. Specific dose availability is something a prescriber confirms at consultation, since stock and clinical suitability both play a role. If you want to explore the realistic chances of NHS access in more detail, that page covers eligibility step by step.

Starting a private consultation if NHS access is not the right route for you

If you have read the NHS criteria above and concluded that the waiting time, the specialist-service requirement or the two-year limit makes private treatment the more practical option, the process at a regulated online pharmacy is straightforward. Consultation is free. A GPhC-registered Independent Prescriber reviews your answers (a real clinician, not an automated filter) on the same day you submit. Identity and weight are verified before any medicine is dispensed. You can read about when NHS prescribing applies if you want to compare the routes side by side, or explore the full Wegovy treatment overview for clinical detail before deciding.

Private treatment is not the right choice for everyone, and a prescriber is the right person to help you weigh it up. If you would like that conversation to start today, check your eligibility with our clinical team.